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ABSTRACT
Mortality rates from critical illness are de-
creasing worldwide, but survivors suffer 
from significant functional disability as a 
result of muscle wasting. In the short-term 
the functional effects are seen in increased 
time of mechanical ventilation, and in-
creased length of stay. Muscle wasting is 
the most common complication of critical 
illness, occurring in 25-50% of patients. In 
a longitudinal observational study, daily 
loss of muscle mass averaged 2-3% over 
the first 10 days. The scale of wasting was 
related to the severity of organ failure and 
of acute lung injury.
Changes in muscle mass are underpinned 
by alterations in muscle protein homeosta-
sis. In stable isotope infusion experiments, 
muscle protein synthesis was reduced to 
levels of fasted controls despite the initia-
tion of enteral feed. Protein synthetic lev-
els recovered variably over the first week 
to levels comparable to fed controls. As a 
result, muscle protein breakdown was in-
creased relative to muscle protein synthe-
sis, leading to a net catabolic state.
There is a need for secondary prevention 
measures  to be instituted in current prac-
tise. Increased nutritional delivery can-
not be recommended at this stage during 
acute critical illness and early mobilisation 
has been demonstrated to increase func-
tional status. This is best achieved through 
the ABCDEF bundle. This bundle consti-
tutes a co-ordinated package of care with 
sedation  control to facilitate spontane-
ous breathing and decreasing delirium. 
This facilitates early mobilisation, which 
is currently the only preventative measure 
with an evidence base to decrease skeletal 
muscle wasting associated functional dis-
ability.
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Mortality rates from critical illness are 
decreasing worldwide, secondary to im-
proved technology and bedside patient 
care. (1) This is coupled with an increase 
in admissions to critical care, secondary to 
both communicable and non-communi-
cable diseases.
In 2003 Herridge et al demonstrated the 
functional disability that patients with 
Acute Respiratory Distress Syndrome 
suffer from 1-year post discharge. Half 
of these patients had still not returned to 
work, and a third needed caregiver as-
sistance for their activities of daily living. 
(2) The average age was 44. Many groups 
around the world have reproduced these 
findings, and we now know that these 
functional disabilities can last for up to 5 
years. (3) 
Patients and researchers both recognize 
muscle wasting and weakness as the great-
est contributor to this functional disabil-
ity. In the short-term the functional effects 
of muscle wasting are seen in increased 
time of mechanical ventilation (4), and in-
creased length of stay. (5)
Muscle mass and quality pre-critical ill-
ness are equally important- in retrospec-
tive studies of Computer Tomography 
scans low admission muscle mass (6) and 
density (7), or the presence of increased 
intra-muscular adipose tissue were associ-
ated with increased mortality. Dissecting 
pre-existing low muscle mass from pre-ex-
isting frailty, disability and or chronic dis-
ease are extremely difficult: these condi-
tions are intertwined in a complex fashion.
Recently more details have emerged on 
the relationship between acute muscle 
wasting and long-term outcomes. Firstly 
patients’ trajectories of weakness post hos-
pital discharge vary considerably, and per-
sistent weakness is associated with worse 
survival. (8) Secondly the older patients 
with co-morbidities are more likely to ex-
perience physical decline and weakness 
post discharge. (9)
Muscle wasting is the most common com-
plication of critical illness, occurring in 
25-50% of patients. (4) Given the signifi-
cant ramifications of acute muscle wasting 
for patients, families and carers, (10, 11) 
clinicians need to understand the patho-
physiology of muscle wasting and develop 
tools for interventions. 
In our longitudinal observational study of 
critically ill patients, daily loss of muscle 
mass averaged 2-3% over the first 10 days. 
(13) Myocellular protein:DNA ratio fell 
steeply (3.0%/day) over the same period. 
The scale of wasting was related to the se-
verity of organ failure and of acute lung 
injury:  Over ten days, those in single or-
gan failure did not lose appreciable muscle 
mass. Those in 2-3 organ failure lost on 
average 20% of muscle mass over 10 days 
and those with greater than 4 organ failure 
lost on average 26% of muscle mass over 
the  same period.
In addition to changes in muscle mass, 
changes in muscle quality were also seen. 
Forty percent of patients demonstrated 
patchy myofibre necrosis, with an associ-
ated fasciitis. These changes were seen on 
muscle biopsy, but were easily detectable 
by qualitative muscle ultrasound. (13) 
Changes in muscle mass were under-
pinned by alterations in muscle protein 
homeostasis. Muscle protein homeostasis 
is the balance of muscle protein break-
down and muscle protein synthesis. In 
health,  muscle protein synthesis is in-
creased in response to protein ingestion 
and/or resistance exercise, and muscle 
protein breakdown switched off by insulin 
release. In humans, unlike rodents, altera-
tions in muscle protein synthesis drive the 
majority of dynamic changes in this bal-
ance, including the response to diverse 
stimuli such as inflammation, immobili-
zation, starvation and aging. In stable iso-
tope infusion experiments, muscle protein 
synthesis was reduced to levels of fasted 
controls despite the initiation of enteral 
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feed. Protein synthetic levels recovered 
variably over the first week to levels com-
parable to fed controls. As a result, muscle 
protein breakdown was increased relative 
to muscle protein synthesis, leading to a 
net catabolic state. The observed changes 
in muscle protein homeostasis were mir-
rored by changes in intracellular  anabolic 
and catabolic signalling pathways. (12)
These results have been reproduced by 
other groups in other countries. (14) 
Whilst ongoing work focuses on develop-
ing interventions for primary prevention, 
there is a need for secondary prevention 
measures  to be instituted in current prac-
tise. Increasing nutritional delivery has not 
been demonstrated to increased muscle 
mass: in  the study described above, in-
creased protein delivery was associated 
with increased muscle wasting. Similarly, 
the EDEN trial demonstrated that trophic 
feeding did not result in decreased mus-
cle strength or function either during the 
acute critical illness or at 1 year. (15) Lastly 
the EPaNIC study (where early parenteral 
nutrition was used to supplement enternal 
nutrition) demonstrated decreased muscle 
mass, decreased autophagy and increased 
intramuscular fat with increasing nutri-
tional delivery. (16)
Whilst increased nutritional delivery can-
not be recommended at this stage during 
acute critical illness, early mobilisation has 
been demonstrated to increase functional 
status within the critical care setting and 
translate to better functional outcomes 
at hospital discharge. (17) This is best 
achieved through the ABCDEF bundle. 
(18) This bundle constitutes a co-ordinat-
ed package of care with sedation  control 
to facilitate spontaneous breathing and 
decreasing delirium. This facilitates early 
mobilisation, which is currently the only 
preventative measure with an evidence 




Acute skeletal muscle wasting occurs 
rapidly and commonly in critical illness. 
Currently early  mobilisation is the only 
secondary preventative measure with an 
evidence based to decrease the associated 
functional disability.
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